AbbVie recommends shareholders reject offer to sell stake to investment group

A capital investment firm is attempting to buy 1.5 million shares of AbbVie common stock at $88.05 per share in a mini-tender offer. 

What you should know:

1. TRC Capital Investment Corp., has turned its eye to AbbVie as the latest target of its mini-tender investment strategy. The firm has developed a reputation for its mini-tender investment strategy, where it attempts to secure a small minority ownership by buying stock for under-market value, according to an article on Seeking Alpha

2. AbbVie released a statement recommending shareholders don't sell to TRC. 

3. AbbVie recommends shareholders obtain current share quotes, review terms and conditions, and consult with their stockbroker before taking any action. 

More articles on ASCs:
The 'new normal' for ASCs: 16 admins on how the pandemic will change the field forever
Dr. Thomas Vikoren: Same-day TJR 'made all the more important' by COVID-19
Indiana orthopedic practice with surgery center to open

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers